Lorcaserin hydrochloride

DRUG3 trials

Sponsors

Eisai Inc., Ohio State University Comprehensive Cancer Center

Conditions

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8

Phase 1

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

CompletedNCT02398669

Eisai Inc.Obesity

Start: 2015-03-31End: 2015-05-31Updated: 2015-11-03

Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer

WithdrawnNCT04205071

Ohio State University Comprehensive Cancer CenterAnatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 +21

Start: 2020-11-01End: 2021-12-31Updated: 2021-01-19

Phase 4

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

CompletedNCT02019264

Eisai Inc.Cardiovascular Disease, High Cardiovascular Risk, Obesity +2

Start: 2014-01-24End: 2018-05-14Updated: 2019-07-16

Related Papers

Statistical approaches for systematically missing covariates in individual participant data meta-analysis: insights and applications using 5 large cardiovascular trials

American Journal of Epidemiology2025-10-08

Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial

Circulation2019-01-1435 citations

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.

2018-10-0454 citations

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

New England Journal of Medicine2018-08-26257 citations

Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.

2018-03-2912 citations